Results 1 to 10 of about 53,515 (238)

Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma [PDF]

open access: yesNew England Journal of Medicine, 2019
BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.
Lars Bastholt   +2 more
exaly   +2 more sources

Nivolumab Plus Ipilimumab Versus Sunitinib in Advanced Renal-Cell Carcinoma [PDF]

open access: yesNew England Journal of Medicine, 2018
Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell ...
Nizar Tannir   +2 more
exaly   +2 more sources
Some of the next articles are maybe not open access.

Overall Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma

New England Journal of Medicine, 2017
James Larkin   +2 more
exaly  

Improved Survival With Ipilimumab in Patients With Metastatic Melanoma

New England Journal of Medicine, 2010
Axel Hoos   +2 more
exaly  

Final, 10-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma

New England Journal of Medicine
Georgina V. Long   +2 more
exaly  

Home - About - Disclaimer - Privacy